Relying solely on single-modality data often fails to comprehensively capture the complex heterogeneity among patients, including variations in resistance to anti-HER2 therapy and differences in the efficacy of combination treatment regimens, particularly in the management of HER2-positive gastric cancer [306]. This evidence concerns the gene ERBB2 and gastric cancer.